Albumin conjugation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Species of Epimedium are herbaceous perennials, growing from an underground rhizome. Their growth habits are somewhat variable. Some have solitary stems, others have a "tufted" habit, with multiple stems growing close together. There may be several leaves to a stem or the leaves may be solitary, produced from the base of the plant. Individual leaves are generally compound, often with three leaflets, but also with more. Leaflets usually have spiny margins. The leaves may be annual, making the plant deciduous, or longer lasting, so that the plant is evergreen. The inflorescence is an open raceme or panicle, the number of flowers varying by species. Individual flowers have parts in fours. There are four smaller outer sepals, usually greenish and shed when the flower opens. Moving inwards, they are followed by four larger petal-like inner sepals, often brightly colored. Inside the sepals are four true petals which may be small and flat, but often have a complex shape including a nectar-producing "spur" that may be longer than the sepals. There are four stamens. One of the common names for the genus, bishop's hat, arises from the shape of the flowers, particularly where the spurs are longer than the sepals.
In medicine, myopathy is a disease of the muscle in which the muscle fibers do not function properly. Myopathy means muscle disease (Greek : myo- muscle + patheia -pathy : suffering). This meaning implies that the primary defect is within the muscle, as opposed to the nerves ("neuropathies" or "neurogenic" disorders) or elsewhere (e.g., the brain). This muscular defect typically results in myalgia (muscle pain), muscle weakness (reduced muscle force), or premature muscle fatigue (initially normal, but declining muscle force). Muscle cramps, stiffness, spasm, and contracture can also be associated with myopathy. Myopathy experienced over a long period (chronic) may result in the muscle becoming an abnormal size, such as muscle atrophy (abnormally small) or a pseudoathletic appearance (abnormally large). Capture myopathy can occur in wild or captive animals, such as deer and kangaroos, and leads to morbidity and mortality. It usually occurs as a result of stress and physical exertion during capture and restraint. Muscular disease can be classified as neuromuscular or musculoskeletal in nature. Different myopathies may be inherited, infectious, non-communicable, or idiopathic (cause unknown). The disease may be isolated to affecting only muscle (pure myopathy), or may be part of a systemic disease as is typical in mitochondrial myopathies.
The fundamental law for the Crown colony of Aden was the Order of Council 28 September 1936, which follows the usual lines of basic legislation for British colonies. The town of Aden was noted as being tied "much more closely into the fabric of the British Empire", with a faster rate of development, than the area surrounding it. Aden was notable in that sharia law was not used in the colony. "All suits, including those dealing with personal status and inheritance of Muslims, are entertained in the ordinary secular courts of the colony". Within Aden Colony, there were three local government bodies. The Aden municipality, which covered the town, Tawali, Ma'alla and Crater, the Township authority of Sheikh Othman and finally Little Aden had been established in recent years as a separate body, covering the oil refinery and the workers' settlement. All of these bodies were under the overall control of the Executive Council, which in turn was kept in check by the Governor. Until 1 December 1955, the Legislative Council was entirely unelected. The situation improved only slightly after this date, as four members were elected. Judicial administration was also entirely in British hands. "Compared with other British possessions, the development towards self-government and greater local participation has been rather slow". Education was provided for all children, both boys and girls, until at least intermediate level. Higher education was available on a selective basis through scholarships to study abroad.
Sources: en.wikipedia.org
==== MeSH D12.776.624.776.355 – cyclin-dependent kinase inhibitor proteins ==== MeSH D12.776.624.776.355.100 – cyclin-dependent kinase inhibitor p15 MeSH D12.776.624.776.355.200 – cyclin-dependent kinase inhibitor p16 MeSH D12.776.624.776.355.300 – cyclin-dependent kinase inhibitor p18 MeSH D12.776.624.776.355.400 – cyclin-dependent kinase inhibitor p19 MeSH D12.776.624.776.355.500 – cyclin-dependent kinase inhibitor p21 MeSH D12.776.624.776.355.600 – cyclin-dependent kinase inhibitor p27 MeSH D12.776.624.776.355.700 – cyclin-dependent kinase inhibitor p57
Fentanyl has started to be mixed into illicitly manufactured opioids and benzodiazepines. Fentanyl contamination in cocaine, methamphetamine, ketamine, MDMA, and other drugs is common. A kilogram of heroin laced with fentanyl may sell for more than US$100,000, but the fentanyl itself may be produced far more cheaply, for about US$6,000 per kilogram. While Mexico and China are the primary source countries for fentanyl and fentanyl-related substances trafficked directly into the United States, India is emerging as a source for finished fentanyl powder and fentanyl precursor chemicals. The United Kingdom illicit drug market is no longer reliant on China, as domestic fentanyl production is replacing imports. The intravenous dose causing 50% of opioid-naive experimental subjects to die (LD50) is "3 mg/kg in rats, 1 mg/kg in cats, 14 mg/kg in dogs, and 0.03 mg/kg in monkeys." The LD50 in mice has been given as 6.9 mg/kg by intravenous administration, 17.5 mg/kg intraperitoneally, 27.8 mg/kg by oral administration, The safety margin in rats is ~280. The LD50 in humans is unknown. In 2023, overdose deaths in the US and Canada reached record numbers. While overdoses involving fentanyl in the United States have decreased in 2024, the overall percentage of overdoses involving fentanyl has remained stable between 70% and 80% from 2021 to 2024. According to a 2023 report from the United Nations Office on Drugs and Crime (UNODC), the increased numbers of deaths are not related to an increased number of users but to the lethal effects of fentanyl itself.
===== Bio-Orthogonal/Quantitative Non-Canonical Amino acid Tagging ===== Bio-Orthogonal/Quantitative Non-Canonical Amino acid Tagging (BONCAT/QuaNCAT) uses azidohomoalanine (AHA) to tag proteins. This allows isolation of newly created proteins for MS. However, using AHA requires predepletion of intracellular methionine and introduction of AHA, stressing the cell and potentially altering translation dynamics within. Similar to pSILAC, AHA methods require longer pulses, thus limiting their efficacy in quantifying nascent peptides.
Sources: en.wikipedia.org
An adnexal mass is a lump in the tissue of the adnexa of the uterus (structures which are closely related structurally and functionally to the uterus, such as the ovaries, fallopian tubes, or any of the surrounding connective tissue). Adnexal masses can be benign (noncancerous) or malignant (cancerous), and they can be categorized as simple or complex.
Acetyl-CoA (acetyl coenzyme A) is a molecule that participates in many biochemical reactions in protein, carbohydrate and lipid metabolism. Its main function is to deliver the acetyl group to the citric acid cycle (Krebs cycle) to be oxidized for energy production. Coenzyme A (CoASH or CoA) consists of a β-mercaptoethylamine group linked to pantothenic acid (vitamin B5) through an amide linkage and 3', 5'-phosphorylated ADP. The acetyl group (indicated in blue in the structural diagram on the right) of acetyl-CoA is linked to the sulfhydryl substituent of the β-mercaptoethylamine group. This thioester linkage is a "high energy" bond, which is particularly reactive. Hydrolysis of the thioester bond is exergonic (−31.5 kJ/mol). CoA is acetylated to acetyl-CoA by the breakdown of carbohydrates through glycolysis and by the breakdown of fatty acids through β-oxidation. Acetyl-CoA then enters the citric acid cycle, where the acetyl group is oxidized to carbon dioxide and water, and the energy released is captured in the form of 11 ATP and one GTP per acetyl group. Konrad Bloch and Feodor Lynen were awarded the 1964 Nobel Prize in Physiology or Medicine for their discoveries linking acetyl-CoA and fatty acid metabolism. Fritz Lipmann won the Nobel Prize in 1953 for his discovery of the cofactor coenzyme A.
Stuart Joseph Patton (November 2, 1920 – October 9, 2017) was an American dairy scientist known for his research in the fields of milk chemistry and the biological processes that regulate milk synthesis in the mammary gland. He was professor of dairy science/food science at Pennsylvania State University from 1949 to 1980 and adjunct professor in the Department of Neurosciences, School of Medicine, University of California, San Diego, and in the School of Family Studies and Consumer Sciences at San Diego State University until his retirement in 2001.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.